Literature DB >> 8990359

Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients.

K V Rao1, J Ma.   

Abstract

To assess the impact of chronic viral hepatitis on host immune response, we analyzed the incidence of acute rejection and the frequency of infections in 86 patients infected with hepatitis B and C viruses and had developed clinical evidence of chronic liver disease and 1283 control patients who were transplanted at our center during the same period, but had no evidence of chronic viral hepatitis. To compare the mean number of rejections and the mean number of infections between the two groups, we used multivariate linear regression analysis, which allowed us to adjust simultaneously for the effects of 10 other risk variables with potential impact on graft rejection and posttransplant infection. During a mean follow up of 5.3+/-5.2 years, 62% of hepatitis patients and 54% of control patients had experienced an acute rejection (P=NS). The mean rejections/patient in the hepatitis group was 1.3+/-0.14 versus 1.03+/-0.03 in control (P=NS). In the linear regression analysis, the number of acute rejections in the hepatitis group was 0.16 higher than in control (P=NS). With reference to infection, 84% of hepatitis patients experienced an infectious complication in the posttransplant period, compared with 75% in the control (P=0.05). The mean number of infections/patient was 5.7+/-0.73 in the hepatitis group compared with 3.9+/-0.14 in the control group (P=0.002). The linear regression model had shown that the hepatitis group had a relative increase of 1.18 infections/pt, compared with control. Of the different sites of infection, the hepatitis group had a significant increase in bloodstream (0.48+/-0.08 vs. 0.25+/-0.02) P=0.003; pulmonary (0.60+/-0.09 vs. 0.38+/-0.03) P=0.03; and CNS infections (0.08+/-0.03 vs. 0.02+/-0.004) P=0.05 compared with control. Among the different microorganisms causing infection, the hepatitis patients had a significant increase in gram negative bacterial infections compared with the control group (74% vs. 61%) P=0.04. Our data suggest that chronic viral hepatitis is associated with a significant increase in overall infections, and that of potentially fatal infections involving CNS, lungs and bloodstream. Since there is no significant increase in the rate of graft rejection, one could consider a cautious reduction in the doses of maintenance immunosuppressive agents in renal transplant patients with chronic viral hepatitis. The reduced immunosuppression may in turn lower the death rate from sepsis and progressive hepatic failure.

Entities:  

Mesh:

Year:  1996        PMID: 8990359     DOI: 10.1097/00007890-199612270-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  The influence of induction therapy for kidney transplantation after a non-renal transplant.

Authors:  James R Cassuto; Matthew H Levine; Peter P Reese; Roy D Bloom; Simin Goral; Ali Naji; Peter L Abt
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

2.  Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression.

Authors:  N Singh; T Gayowski; M M Wagener; I R Marino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

3.  HCV-infected Renal Transplant Recipients: Our Experience before the Availability of New Antiviral Drugs.

Authors:  A R Fernandes; I J Laranjinha; R Birne; P Matias; C Jorge; T Adragão; M Bruges; A Weigert; D Machado
Journal:  Int J Organ Transplant Med       Date:  2017-05-01

4.  The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral era.

Authors:  Radhika Chemmangattu Radhakrishnan; Basu Gopal; Uday G Zachariah; Priya Abraham; Anjali Mohapatra; Anna T Valson; Suceena Alexander; Shibu Jacob; Kakde Shailesh Tulsidas; Vinoi G David; Santosh Varughese
Journal:  Saudi J Kidney Dis Transpl       Date:  2018 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.